Jun 9, 2026 08:01AM
Jun 9, 2026 08:00AM
May 14, 2026 04:15PM
May 14, 2026 04:15PM
Apr 20, 2026 05:00PM
Apr 20, 2026 05:00PM
Mar 26, 2026 04:01PM Alpha Cognition reports $10.2 million in 2025 revenue from ZUNVEYL sales
Mar 26, 2026 04:01PM
Mar 10, 2026 08:30AM
Feb 18, 2026 08:30AM
Feb 18, 2026 08:30AM
Dec 1, 2025 05:51PM
Nov 13, 2025 04:00PM
Oct 14, 2025 04:30PM Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings
Oct 6, 2025 08:30AM
Aug 14, 2025 08:30AM
Jul 29, 2025 08:32AM
Jul 29, 2025 08:30AM
Jul 8, 2025 08:30AM
Jul 1, 2025 05:05PM
Jul 1, 2025 05:05PM Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
May 15, 2025 08:30AM
Apr 30, 2025 07:30AM
Apr 28, 2025 08:30AM
Apr 10, 2025 08:30AM
Mar 18, 2025 08:30AM
Jan 8, 2025 08:32AM
Jan 8, 2025 08:30AM Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer�
Jan 6, 2025 08:30AM
Nov 15, 2024 05:00PM
Nov 12, 2024 09:22AM
Oct 15, 2024 08:30AM
Sep 24, 2024 05:16PM
Aug 19, 2024 08:30AM
Aug 12, 2024 04:35PM Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
Jul 29, 2024 08:08AM
May 14, 2024 07:24PM
Apr 3, 2024 10:08PM
Mar 1, 2024 07:53AM
Feb 22, 2024 08:30AM
Feb 12, 2024 08:30AM
Dec 7, 2023 04:35PM Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
Nov 28, 2023 04:45PM
Sep 27, 2023 04:30PM
Aug 22, 2023 04:05PM
May 30, 2023 12:15PM
Mar 8, 2023 06:24PM
Jan 19, 2023 03:00PM
Nov 28, 2022 04:30PM Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update
Nov 28, 2022 01:40PM

322,899 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All